Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit

PJ Van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - Elsevier
BACKGROUND: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …

[HTML][HTML] A detailed evaluation of the effect of prostate-specific antigen–based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the …

II de Vos, A Meertens, R Hogenhout, S Remmers… - European Urology, 2023 - Elsevier
Background Considering the long natural history of prostate cancer (PCa), long-term results
of the European Randomised Study of Screening for PCa (ERSPC) are crucial. Objective To …

Prostate cancer mortality in the Finnish randomized screening trial

TP Kilpeläinen, TL Tammela, N Malila… - Journal of the …, 2013 - academic.oup.com
Background Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been
shown to decrease PC mortality by the European Randomized Study of Screening for …

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer

MJ Roobol, R Kranse, CH Bangma, AG van Leenders… - European urology, 2013 - Elsevier
Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …

Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer

C Buzzoni, A Auvinen, MJ Roobol, S Carlsson… - European urology, 2015 - Elsevier
Abstract Background The European Randomized Study of Screening for Prostate Cancer
(ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold …

Balancing the harms and benefits of early detection of prostate cancer

PJ Van Leeuwen, D Connolly, TLJ Tammela… - Cancer, 2010 - Wiley Online Library
BACKGROUND: The benefits of prostate cancer screening on an individual level remain
unevaluated. METHODS: Between 1993 and 1999, a total of 43,987 men, aged 55‐74 …

Prostate cancer mortality reduction by prostate-specific antigen–based screening adjusted for nonattendance and contamination in the European Randomised Study …

MJ Roobol, M Kerkhof, FH Schröder, J Cuzick… - European urology, 2009 - Elsevier
BACKGROUND: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa)
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …

4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam

FH Schröder, R Raaijmakers, R Postma… - The Journal of …, 2005 - auajournals.org
ABSTRACT Purpose: The European Randomized Study of Screening for Prostate Cancer
investigates the impact of screening on prostate cancer mortality and contributes to a better …

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

J Hugosson, MJ Roobol, M Månsson, TLJ Tammela… - European urology, 2019 - Elsevier
Abstract Background The European Randomized study of Screening for Prostate Cancer
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …

Screening and prostate-cancer mortality in a randomized European study

FH Schröder, J Hugosson, MJ Roobol… - New England journal …, 2009 - Mass Medical Soc
Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen …